ACM
PTCT icon

Aster Capital Management’s PTC Therapeutics PTCT Stock Holding History

Aster Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-98
Closed -$4.42K – 1597
2024
Q4 		$4.42K Buy
+98
New +$4.19K ﹤0.01% 874

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aster Capital Management's PTCT Position: Q1 2025 in Review

Aster Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 98 shares — an estimated $4.42K sold.

Aster Capital Management first reported a position in PTCT in Q4 2024 and held it in 1 quarter. The position peaked at $4.42K in Q4 2024. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

  • Aster Capital Management reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aster Capital Management sold 98 PTC Therapeutics shares in Q1 2025, an estimated $4.42K.
  • Aster Capital Management first reported a position in PTC Therapeutics in Q4 2024 and held it in 1 quarter.
  • Aster Capital Management's PTC Therapeutics position peaked at $4.42K in Q4 2024.
  • 260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Aster Capital Management's 13F filing for Q1 2025, filed 15 May 2025.